ITOC 2022 | CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer

Mascha Binder • 19 Sep 2022

CAR-T & Cellular Therapy Immuno-Oncology

Mascha Binder, MD, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany, discusses the generation of CAR-T cells expressing a scFV targeting the hTSHR in thyroid cancer. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Chemotherapy and immunotherapy: to combine or not to combine?

Mascha Binder • 19 Sep 2022

The prognostic potential of liquid biopsy in advanced HER2 positive esophagogastric adenocarcinoma

Mascha Binder • 19 Sep 2022

The selection of PD-L1 escape variants in microsatellite stable metastatic CRC on avelumab treatment

Mascha Binder • 19 Sep 2022

Related Videos

New thyroid cancer trials: questioning ablative radioiodine and exploring resensitization

Jonathan Wadsley • 8 Nov 2018

HiLo: low risk thyroid cancer can be treated with lower doses of radiation

Jonathan Wadsley • 8 Nov 2018

TKIs for treating medullary thyroid cancer

Jolanta Krajewska • 29 Nov 2018

FDA approval of selpercatinib for RET fusion positive NSCLC and thyroid cancers

Vivek Subbiah • 25 May 2020